RE:RE:RE:RE:RE:“Second mouse gets the cheese “March 21, 2024 - Swiss contract manufacturer Lonza has agreed to acquire the Genentech large-scale biologics manufacturing facility in Vacaville, California, US, from Roche in a $1.2bn deal.
This move to shed this sort of large-scale biologics manufacturing appears to signal that Genentech is leaning-in on further partnering with specialized biologic "vaccine" manufacturing that BioNTech has acquired in developing mnufacturing capacities for the Pfizer mRNA Covid-19 vaccine Comirnaty, and that aligns with ONCY's lyophilized manufacturing of pelareorep currently produced by Merck KGaA's Millipore Sigma.
These events are beginning to place pressure on Merck KGaA to become an active player in the acquisition of ONCY, as a potential acquirer of ONCY.
https://www.pharmaceutical-technology.com/news/lonza-roche-site/